A treatment of patients afflicted with Amyotrophic Lateral Sclerosis (ALS), wherein the patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one pharmaceutically active ingredient
